|
|
|
|
|
|
By Jeffrey S. Buguliskis, Ph.D., chief editor, Outsourced Pharma | As biopharma pipelines shift toward more complex therapies, sponsors are finding that CDMO readiness now depends less on general capacity and more on highly specific technical capabilities. | |
|
|
|
|
| A Continuous Electroporation System For Viral Gene Therapy | Article | By Takashi Yakushiji and Yoichi Nagai, FUJIFILM Biotechnologies | Gain insight into the specialized engineering behind chemical-free, continuous platforms. These scalable systems streamline production workflows while eliminating hazardous reagents. |
|
|
| Scaling AAV Programs From Initial Research To GMP Manufacturing | Application Note | By Suparna Sanyal and Peng Wang, Lonza | Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields. |
|
|
|
|
|
|
|
|
|
| OPT Congress 2026 convenes the leaders advancing oligonucleotide, mRNA, and peptide therapeutics from discovery through commercialization. Across four focused conferences, explore 60+ presentations covering AI-enabled design, next-generation delivery, scalable manufacturing, and emerging conjugate platforms. Join a high-level community driving real translational impact. Use code OPS26ARNA for $200 off registration. Download the brochure to view the full agenda and secure your place March 18–19 in Boston or virtually. |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
